These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20187101)

  • 41. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
    Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
    Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
    Strati P; Lanasa M; Call TG; Leis JF; Brander DM; LaPlant BR; Pettinger AM; Ding W; Parikh SA; Hanson CA; Chanan-Khan AA; Bowen DA; Conte M; Kay NE; Shanafelt TD
    Lancet Haematol; 2016 Sep; 3(9):e407-14. PubMed ID: 27570087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
    Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
    Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
    Nabhan C; Gartenhaus RB; Tallman MS
    Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
    Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
    Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
    Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
    J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
    Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
    Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
    Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
    Di Bella N; Reynolds C; Faragher D; Muscato J; Boehm KA; Asmar L
    Cancer; 2005 Mar; 103(5):978-84. PubMed ID: 15672388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
    Hillmen P
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
    Tedeschi A; Rossi D; Motta M; Quaresmini G; Rossi M; Coscia M; Anastasia A; Rossini F; Cortelezzi A; Nador G; Scarfò L; Cairoli R; Frustaci AM; Dalceggio D; Picardi P; De Paoli L; Orlandi E; Rambaldi A; Massaia M; Gaidano G; Montillo M;
    Haematologica; 2015 Dec; 100(12):e501-4. PubMed ID: 26294723
    [No Abstract]   [Full Text] [Related]  

  • 60. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.